ORGO

MKT CAP:$307M

Organogenesis Holdings Inc.

Market Cap

$307M

Healthcare·Drug Manufacturers - Specialty & Generic·🇺🇸 United States·NASDAQ

Healthcare·Drug·🇺🇸·NASDAQ

Stock Price

$2.38-$2.25 (-48.60%)

Apr 23, 2026

Company Details

Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care ...

CEO

Gary S. Gillheeney

IPO Date

Jan 5, 2017

Website

organogenesis.com

Key Metrics TTM

Revenue

$564M

+17.0% YoY

Net Income

$37M

EPS (Diluted)

$0.11

Free Cash Flow

-$24M

Revenue / Share

$4.27

Gross Margin

74.4%

Operating Margin

8.3%

Net Margin

6.6%

FCF Margin

-4.3%

P/S

0.5x

P/E

8.3x

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Feb 26, 2026

$564M+17.0%EPS $0.15

Q4 2025

Feb 26, 2026

$226M+78.1%EPS $0.27

Q3 2025

Nov 6, 2025

$151M+31.0%EPS $0.11

Q2 2025

Aug 7, 2025

$101M-22.6%EPS -$0.10

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$97M	$72M	-$128.0K
Q2 22	$121M	$95M	$12M
Q3 22	$117M	$91M	$2M
Q4 22	$116M	$88M	$9M
Q1 23	$108M	$81M	-$4M
Q2 23	$117M	$91M	$10M
Q3 23	$109M	$83M	$8M
Q4 23	$100M	$72M	-$1M
Q1 24	$110M	$81M	-$4M
Q2 24	$130M	$101M	-$14M
Q3 24	$115M	$88M	$6M
Q4 24	$127M	$96M	$10M
Q1 25	$87M	$63M	-$27M
Q2 25	$101M	$73M	-$13M
Q3 25	$151M	$115M	$21M
Q4 25	$226M	$169M	$65M

Valuation

Quarter	P/S	P/E
Q1 22	2.0x	11.2x
Q2 22	1.4x	8.8x
Q3 22	0.9x	7.1x
Q4 22	0.8x	22.8x
Q1 23	0.6x	20.8x
Q2 23	1.0x	43.8x
Q3 23	0.9x	29.9x
Q4 23	1.4x	118.8x
Q1 24	0.8x	63.0x
Q2 24	0.8x	—
Q3 24	0.8x	—
Q4 24	0.9x	486.6x
Q1 25	1.2x	—
Q2 25	1.1x	—
Q3 25	1.2x	537.7x
Q4 25	1.2x	17.9x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	$1M	-$5M
Q2 22	$10M	$4M
Q3 22	$5M	-$5M
Q4 22	$8M	-$3M
Q1 23	-$5M	-$13M
Q2 23	$9M	$1M
Q3 23	$17M	$11M
Q4 23	$11M	$7M
Q1 24	-$10M	-$12M
Q2 24	$5M	$3M
Q3 24	$9M	$6M
Q4 24	$11M	$8M
Q1 25	-$20M	-$24M
Q2 25	-$33M	-$37M
Q3 25	$3M	$844.0K
Q4 25	$39M	$35M

Capital Expenditures

Quarter	CapEx
Q1 22	$7M
Q2 22	$6M
Q3 22	$10M
Q4 22	$11M
Q1 23	$8M
Q2 23	$7M
Q3 23	$6M
Q4 23	$3M
Q1 24	$2M
Q2 24	$2M
Q3 24	$3M
Q4 24	$3M
Q1 25	$4M
Q2 25	$4M
Q3 25	$2M
Q4 25	$5M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-5.3%	+8.1%
Q2 22	-1.5%	+9.9%
Q3 22	+2.7%	+18.0%
Q4 22	-10.1%	-1.2%
Q1 23	+10.8%	+14.8%
Q2 23	-3.4%	-1.7%
Q3 23	-7.1%	-12.7%
Q4 23	-13.7%	-5.5%
Q1 24	+2.2%	+2.0%
Q2 24	+11.0%	+34.0%
Q3 24	+6.1%	+8.4%
Q4 24	+27.1%	+15.4%
Q1 25	-21.2%	-0.3%
Q2 25	-22.6%	-21.4%
Q3 25	+31.0%	+19.5%
Q4 25	+78.1%	+37.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$1M	1.3%
Q2 22	$2M	1.4%
Q3 22	$0	0.0%
Q4 22	$2M	1.6%
Q1 23	$2M	1.8%
Q2 23	$2M	2.0%
Q3 23	$2M	2.2%
Q4 23	$2M	2.4%
Q1 24	$2M	2.2%
Q2 24	$3M	2.0%
Q3 24	$3M	2.4%
Q4 24	$0	0.0%
Q1 25	$3M	3.9%
Q2 25	$3M	2.5%
Q3 25	$0	0.0%
Q4 25	$4M	1.9%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 22	$9M	—	—	$64M
Q2 22	$10M	$73M	—	—
Q3 22	$10M	—	—	$79M
Q4 22	$11M	—	—	$68M
Q1 23	$11M	—	—	$74M
Q2 23	$11M	$70M	—	—
Q3 23	$10M	—	—	$64M
Q4 23	$12M	—	—	$61M
Q1 24	$13M	—	—	$72M
Q2 24	$16M	—	—	$77M
Q3 24	$10M	—	—	$72M
Q4 24	$12M	$70M	$4M	—
Q1 25	$11M	—	—	$73M
Q2 25	$10M	—	—	$74M
Q3 25	$13M	—	—	$79M
Q4 25	$10M	—	—	$100M

Revenue Segments

Quarter	Advanced Wound care	Surgical and Sports Medicine	Grant	Product
Q1 22	$91M	$7M	—	—
Q2 22	$114M	$8M	—	—
Q3 22	$110M	$7M	—	—
Q4 22	$109M	$7M	—	—
Q1 23	$101M	$7M	—	—
Q2 23	$110M	$7M	—	—
Q3 23	$101M	$7M	—	—
Q4 23	$93M	$6M	—	—
Q1 24	$104M	$6M	—	—
Q2 24	$123M	$7M	—	—
Q3 24	$108M	$7M	—	—
Q1 25	$80M	$7M	—	—
Q2 25	—	—	$226.0K	$101M
Q3 25	—	—	$377.0K	$150M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$108M	$0	$108M
Q2 22	$112M	$0	$112M
Q3 22	$107M	$0	$107M
Q4 22	$102M	$0	$102M
Q1 23	$89M	$0	$89M
Q2 23	$89M	$0	$89M
Q3 23	$98M	$0	$98M
Q4 23	$104M	$0	$104M
Q1 24	$89M	$0	$89M
Q2 24	$90M	$0	$90M
Q3 24	$94M	$0	$94M
Q4 24	$136M	$0	$136M
Q1 25	$110M	$0	$110M
Q2 25	$73M	$0	$73M
Q3 25	$64M	$0	$64M
Q4 25	$94M	$0	$94M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	133M	-0.4%	-0.5%
Q2 22	133M	-0.2%	-1.0%
Q3 22	132M	-0.3%	-1.2%
Q4 22	132M	-0.3%	-1.1%
Q1 23	131M	-0.6%	-1.3%
Q2 23	133M	+1.5%	+0.4%
Q3 23	133M	+0.3%	+0.9%
Q4 23	132M	-1.2%	0.0%
Q1 24	132M	+0.0%	+0.6%
Q2 24	133M	+0.5%	-0.4%
Q3 24	134M	+1.0%	+0.4%
Q4 24	132M	-1.3%	+0.2%
Q1 25	126M	-4.4%	-4.2%
Q2 25	127M	+0.4%	-4.3%
Q3 25	131M	+3.1%	-2.3%
Q4 25	132M	+1.0%	+0.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$102.2K	950
Q2 22	$127.8K	950
Q3 22	$123.0K	950
Q4 22	$112.2K	1K
Q1 23	$104.5K	1K
Q2 23	$113.9K	1K
Q3 23	$105.4K	1K
Q4 23	$115.6K	862
Q1 24	$127.6K	862
Q2 24	$151.1K	862
Q3 24	$133.6K	862
Q4 24	$145.7K	869
Q1 25	$99.8K	869
Q2 25	$116.0K	869
Q3 25	$173.6K	869
Q4 25	$264.2K	854

Revenue / Employee